Creatine Monohydrate In Myotonic Dystrophy: A Double-blind, Placebo-controlled Clinical Study
| 効果 | 増加 |
| 試験方法 | 二重盲検法 |
| 試験期間 | 1-6 ヶ月 |
| 被験者数 | 34 |
| 性別 | 男女 |
| 年齢 | 30-44, 45-64 |
| 体型 | 平均 |
Individuals with myotonic dystrophy received 10.6 g/day for 10 days followed by 5.3 g/day for 46 days. No effect was noted until the second half of the study (it was a cross-over design), when some of the parameters that worsened in the placebo group improved in the creatine group. The improvement was slight, if statistically significant, which suggest very minor therapeutic benefits.
Creatine Monohydrate Supplementation Does Not Increase Muscle Strength, Lean Body Mass, Or Muscle Phosphocreatine In Patients With Myotonic Dystrophy Type 1
| 効果 | なし |
| 試験方法 | 二重盲検法 |
| 試験期間 | 1-6 ヶ月 |
| 被験者数 | 34 |
| 性別 | 男女 |
| 年齢 | 45-64, 65+ |
| 体型 | 平均 |
5 g/day for 4 months in individuals with myotonic dystrophy type I (DM1) failed to improve muscular strength (handgrip) or lung function (FEV1) relative to placebo, nor was there any influence on functional tests or biochemical parameters.
Creatine Monohydrate In DM2/PROMM: A Double-blind Placebo-controlled Clinical Study. Proximal Myotonic Myopathy
| 効果 | 増加 |
| 試験方法 | 二重盲検法 |
| 試験期間 | 1-6 ヶ月 |
| 被験者数 | 20 |
| 性別 | 男女 |
| 年齢 | 45-64 |
| 体型 | 平均 |
10 g/day for 3 months in individuals with myotonic dystrophy type II (DM2 or PROMM) failed to alter power output but significantly improved subjective well-being relative to placebo (mainly less exhaustion following physical exercise).